ATRA vs CVS · rev $128.9M vs P/E 16, rev $402.07B
Atara Biotherapeutics Inc (ATRA) versus CVS Health Corp (CVS) — a side-by-side from cached financials, not a winner call.
Atara Biotherapeutics Inc (ATRA) is a biotechnology company listed on NASDAQ.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
Latest reported ATRA revenue for 2024-12-31 was $128.9M. Net income was -$85.4M. Revenue was up 1404.0% from 2023-12-31 to 2024-12-31. ATRA currently screens at market cap $87.1M.
Latest reported CVS revenue for 2025-12-31 was $402.07B. Net income was $1.77B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
ATRA currently screens at market cap $87.1M. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
Not investment advice. Open the ATRA and CVS stock pages for the full models.
Not investment advice.